Breast cancer and [vic-]trastuzumab duocarmazine (SYD985) and
In a recent press release by Byondis, the pharmaceutical company expressed excitement and optimism about the clinical results of their new drug, [vic-]trastuzumab duocarmazine (SYD985).
The purpose of the clinical trial is to compare the effectiveness of [vic-]trastuzumab duocarmazine with a physician’s choice of chemotherapy. In other words, a set of patients in the study received [vic-]trastuzumab duocarmazine, whereas another group took a combination of chemotherapy drugs recommended by an oncologist.
What is [Vic-]trastuzumab duocarmazine?
[Vic-]trastuzumab duocarmazine is a drug that targets cancer cells. It contains a monoclonal antibody –trastuzumab – and valine-citrulline-seco-DUocarmycin-hydroxyBenzamide-Azaindole, a cleavable linker-drug.
FDA approval of trastuzumab duocarmazine
The approval was encouraged by the results of the second part of the phase 1 trial, which showed:
- Objective response rate (ORR) of 33%
- Median progression-free survival (PFS) of 9.4 months
Progression-free survival (PFS) – this parameter is defined as the time during or after receiving cancer treatment when the patient lives with the disease, but it does not get worse.
The details of the study which is called the “TULIP trial”
The criteria for enrollment included:
Age – participants had to be above 18 years old
Treatment progress – progressed during or after at least 2 HER2-targeting treatment regimens for locally advanced or metastatic disease
The patients were then randomized to receive [Vic-]trastuzumab duocarmazine or a physician’s choice of chemotherapy. Note that the treatment with either drug persisted until toxicity reached intolerable levels
To analyze the results objectively, researchers assessed for the following clinical parameters:
Hopefully, the detailed results of the TULIP trial will reveal more information about the superiority of trastuzumab duocarmazine over a physician’s choice of chemotherapy.
Takeaway message for breast cancer patients
The initial results released by this study give both patients and physicians hope about the clinical advances that can be provided by [Vic-]trastuzumab duocarmazine in the treatment of HER2-positive metastatic breast cancer.
We hope that this article managed to simplify this complex topic into understandable bits.
Talk to us so see if we can help you to actually get the most advanced treatments
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039
About Breast cancer>>